|
Apr 14
|
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers
|
|
Apr 8
|
High Growth Tech Stocks In The US To Watch April 2025
|
|
Mar 12
|
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...
|
|
Mar 10
|
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 10
|
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
|
|
Feb 27
|
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
|
|
Feb 25
|
Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?
|
|
Feb 24
|
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
|
|
Feb 21
|
UroGen acquires IconOVir’s oncolytic virus assets
|
|
Feb 20
|
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
|
|
Feb 14
|
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
|
|
Feb 12
|
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology
|
|
Dec 31
|
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)
|
|
Oct 9
|
UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
|
|
Oct 9
|
UroGen Appoints Chris Degnan as Chief Financial Officer
|
|
Oct 3
|
UroGen begins subject dosing in Phase III bladder cancer drug trial
|
|
Oct 2
|
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
|
Aug 29
|
UroGen Pharma to Present at Upcoming Investor Conferences
|
|
Aug 16
|
UroGen Pharma Ltd. (NASDAQ:URGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$43.88
|
|
Jun 27
|
UroGen Pharma Stock Earns 91 RS Rating
|